Pegfilgrastim in children with severe congenital neutropenia

Francesca Fioredda, Michaela Calvillo, Marina Lanciotti, Tiziana Lanza, Laura Giunti, Elio Castagnola, Ines Lorenzi, Rossella Tonelli, Piero Ghezzi, Carlo Dufour

Research output: Contribution to journalArticlepeer-review


Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.

Original languageEnglish
Pages (from-to)465-467
Number of pages3
JournalPediatric Blood and Cancer
Issue number3
Publication statusPublished - Mar 2010


  • Filgrastim
  • Pegfilgrastim
  • R-Hu-granulocyte-stimulating factor
  • Severe congenital neutropenia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Pegfilgrastim in children with severe congenital neutropenia'. Together they form a unique fingerprint.

Cite this